Grants Funded
Grant applicants for the 2024 cycle requested a total of nearly $3 million dollars. The PSF Study Section Subcommittees of Basic & Translational Research and Clinical Research evaluated more than 100 grant applications on the following topics:
The PSF awarded research grants totaling over $650,000 dollars to support more than 20 plastic surgery research proposals.
ASPS/PSF leadership is committed to continuing to provide high levels of investigator-initiated research support to ensure that plastic surgeons have the needed research resources to be pioneers and innovators in advancing the practice of medicine.
Research Abstracts
Search The PSF database to have easy access to full-text grant abstracts from past PSF-funded research projects 2003 to present. All abstracts are the work of the Principal Investigators and were retrieved from their PSF grant applications. Several different filters may be applied to locate abstracts specific to a particular focus area or PSF funding mechanism.
Lymphatic Inhibition and Dendritic Cells
Justin Sacks MD, MBA
2013
Johns Hopkins University
Pilot Research Grant
Composite Tissue Allotransplantation, General Reconstructive
Vascularized composite allotransplantation (VCA) is a recently developed method for reconstructing patients with complex and severe disfigurements. However, patients must take immunosuppressants for the rest of their life. Immunosuppressants have many drawbacks, including risks of cancer and severe metabolic and endocrine disturbances. Therefore, much attention is being given to methods that reduce the need for immunosuppression. One such method may be inhibiting the lymphatic system at the time of transplantation. Lymphatics act as highways for immune cells in the skin to reach the lymph node and activate the immune response. Inhibiting lymphatics has already been shown to reduce the threat of graft rejection in several other organ transplant models. However, it may be particularly powerful in VCA because the skin component, which the recipient's immune system attacks most vigorously, has an extensive network of lymphatic vessels. In this proposal, we will: 1) study how inhibiting lymphatic regeneration affects skin rejection, 2) how immunosuppressants affect lymphatic regeneration, and 3) how inhibiting lymphatic regeneration affects immune cell trafficking. To study our first aim, we will transfer skin from transgenic mice with no lymphatics in their skin to normal mice and measure the time to skin rejection. To study our second aim, we will treat mice receiving skin grafts with different immunosuppressants, and assess how regeneration patterns and levels of lymphatic-specific growth factors are affected. Finally, to study our third aim, we will use a laser to ablate lymphatics and then track the movements of immune cells to see if their trafficking is inhibited. If successful, our work will demonstrate that inhibiting lymphatic reconstitution indeed holds promise to reduce the threat of acute rejection in VCA. Future work may determine whether we can use this to reduce the dose of immunosuppression, increasing the availability of VCA.
